丹珍头痛胶囊治疗高血压头痛68例临床观察

目的：探究丹珍头痛胶囊治疗高血压头痛的临床疗效。方法高血压头痛患者68例采用随机数字表法分为治疗组（n ＝38）和对照组（n ＝30）。对照组单采用常规降压治疗;治疗组在对照组基础上加用丹珍头痛胶囊治疗。比较两组临床疗效。结果治疗组高血压头痛症状得到缓解的总有效率显著高于对照组（84．21％比53．33％）,差异有统计学意义（χ2＝7．992,P ＜0．05）,且无毒副反应。结论丹珍头痛胶囊治疗高血压头痛疗效肯定,可作为改善临床症状的首选药,值得临床进一步研究和推广。     

早期集束化治疗在经皮肾镜碎石术后感染性休克患者的应用价值

目的：探索早期集束化治疗在经皮肾镜碎石（PCNL ）术后感染性休克患者的应用价值。方法回顾性分析2011年1月至2013年9月因PCNL术后并发感染性休克入住该院中心ICU的患者,根据是否采取感染性休克集束化治疗分为非集束化治疗组28例,集束化治疗组26例。比较两组患者治疗前、治疗后第1、3、5天APACHE‐Ⅱ评分和SOFA评分,ICU停留时间情况。根据28 d随访结果比较两组患者病死率。结果同非集束化治疗组比较,集束化治疗组第1、3、7天APACHE‐Ⅱ评分和SOFA评分均明显降低,差异有统计学意义（P＜0．05）。随访28 d ,集束化治疗组患者病死率（15．38％）明显低于非集束化治疗组（35．71％） ,差异有统计学意义（ P＜0．05）。非集束化治疗组和集束化治疗组患者IC U 停留时间分别为（9．04±4．48）d和（7．00±2．32）d ,差异有统计学意义（ P＜0．05）。结论早期集束化治疗有利于减轻PC N L术后感染性休克患者病情严重程度,减少病死率。     

真性完全性左束支阻滞情况调查分析

目的：了解完全性左束支阻滞及真性完全性左束支阻滞在不同性别与年龄的发生率情况。方法分析620888例12导联静息心电图检测结果,统计完全性左束支阻滞不同年龄、不同性别的发生率情况。结果完全性左束支阻滞发生率在不同性别之间差异无显著性(Χ2=0.6771,P=0.4106),真性完全性左束支阻滞发生率在不同性别之间差异有显著性(Χ2=15.261,P<0.05)。完全性左束支阻滞发生率与年龄存在相关性(Χ2=671.8555,P<0.05);真性完全性左束支阻滞发生率与年龄存在相关性(Χ2=299.9378, P<0.05)。结论根据本研究推断女性发生真性完全性左束支阻滞即左束支传导功能彻底丧失的概率比男性低,因此在临床工作中女性出现完全性左束支阻滞应仔细判别,是否为左束支功能完全丧失,为临床治疗提供坚实的基础。     

Sinus node exit,crista terminalis conduction,interatrial connection,and wavefront collision: Key features of human atrial activation in sinus rhythm

1. Download : Download high-res image (359KB)
2. Download : Download full-size image

     

Yttrium-90 Radioembolization to the Prostate Gland: Proof of Concept in a Canine Model and Clinical Translation

PurposeTo investigate the feasibility, safety, and absorbed-dose distribution of prostatic artery radioembolization (RE) in a canine model.Materials and MethodsFourteen male castrated beagles received dihydroandrosterone/estradiol to induce prostatic hyperplasia for the duration of the study. Each dog underwent fluoroscopic prostatic artery catheterization. Yttrium-90 (⁹⁰Y) microspheres (TheraSphere; Boston Scientific, Marlborough, Massachusetts) were delivered to 1 prostatic hemigland (dose escalation from 60 to 200 Gy), with the contralateral side serving as a control. Assessments for adverse events were performed throughout the follow-up (Common Terminology Criteria for Adverse Events v5.0). Positron emission tomography/magnetic resonance (MR) imaging provided a confirmation after the delivery of absorbed-dose distribution. MR imaging was performed before and 3, 20, and 40 days after RE. Tissue harvest of the prostate, rectum, bladder, urethra, penis, and neurovascular bundles was performed 60 days after RE.ResultsAll the animals successfully underwent RE. Positron emission tomography/MR imaging demonstrated localization to and good coverage of only the treated hemigland. No adverse events occurred. The MR imaging showed a significant dose-dependent decrease in the treated hemigland size at 40 days (25%–60%, P < .001). No extraprostatic radiographic changes were observed. Necropsy demonstrated no gross rectal, urethral, penile, or bladder changes. Histology revealed RE-induced changes in the treated prostatic tissues of the highest dose group, with gland atrophy and focal necrosis. No extraprostatic RE-related histologic findings were observed.ConclusionsProstate ⁹⁰Y RE is safe and feasible in a canine model and leads to focal dose-dependent changes in the gland without inducing unwanted extraprostatic effects. These results suggest that an investigation of nonoperative prostate cancer is warranted.